Skip to main content

Advertisement

SpringerLink
Log in

Radiogenomics in renal cell carcinoma

  • Published:
Abdominal Radiology Aims and scope Submit manuscript

Abstract

Radiogenomics, a field of radiology investigating the association between the imaging features of a disease and its gene expression pattern, has expanded considerably in the last few years. Recent advances in whole-genome sequencing of clear cell renal cell carcinoma (ccRCC) and the identification of mutations with prognostic significance have led to increased interest in the relationship between imaging and genomic data. ccRCC is particularly suitable for radiogenomic analysis as the relative paucity of mutated genes allows for more straightforward genomic-imaging associations. The ultimate aim of radiogenomics of ccRCC is to retrieve additional data for accurate diagnosis, prognostic stratification, and optimization of therapy. In this review article, we will present the state-of-the-art of radiogenomics of ccRCC, and after briefly reviewing updates in genomics, we will discuss imaging-genomic associations for diagnosis and staging, prognosis, and for assessment of optimal therapy in ccRCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Kuo MD, Jamshidi N (2014) Behind the numbers: decoding molecular phenotypes with radiogenomics-guiding principles and technical considerations. Radiology 270(2):320–325

    Article  PubMed  Google Scholar 

  2. Lander ES, Linton LM, Birren B, et al. (2001) Initial sequencing and analysis of the human genome. Nature 409(6822):860–921

    Article  CAS  PubMed  Google Scholar 

  3. Alessandrino F, Krajewski KM, Shinagare AB (2016) Update on radiogenomics of clear cell renal cell carcinoma. Eur Urol Focus 2(6):572–573

    Article  PubMed  Google Scholar 

  4. Kuo MD, Gollub J, Sirlin CB, Ooi C, Chen X (2007) Radiogenomic analysis to identify imaging phenotypes associated with drug response gene expression programs in hepatocellular carcinoma. J Vasc Interv Radiol 18(7):821–831

    Article  PubMed  Google Scholar 

  5. Diehn M, Nardini C, Wang DS, et al. (2008) Identification of noninvasive imaging surrogates for brain tumor gene-expression modules. Proc Natl Acad Sci USA 105(13):5213–5218

    Article  PubMed  PubMed Central  Google Scholar 

  6. Rutman AM, Kuo MD (2009) Radiogenomics: creating a link between molecular diagnostics and diagnostic imaging. Eur J Radiol 70(2):232–241

    Article  PubMed  Google Scholar 

  7. The Cancer Genome Atlas Research Network (2013) Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499(7456):43–49

    Article  CAS  PubMed Central  Google Scholar 

  8. Karlo CA, Di Paolo PL, Chaim J, et al. (2014) Radiogenomics of clear-cell renal cell carcinoma: associations between CT imaging features and mutations. Radiology 270(2):464–471

    Article  PubMed  Google Scholar 

  9. Shinagare AB, Vikram R, Jaffe C, et al. (2015) Radiogenomics of clear cell renal cell carcinoma: preliminary findings of The Cancer Genome Atlas-Renal Cell Carcinoma (TCGA–RCC) Imaging Research Group. Abdom Imaging 40(6):1684–1692

    Article  PubMed  PubMed Central  Google Scholar 

  10. Seizinger BR, Rouleau GA, Ozelius LJ, et al. (1988) Von Hippel–Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Nature 332(6161):268–269

    Article  CAS  PubMed  Google Scholar 

  11. Dalgliesh GL, Furge K, Greenman C, et al. (2010) Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 463(7279):360–363

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Duns G, van den Berg E, van Duivenbode I, et al. (2010) Histone methyltransferase gene SETD2 is a novel tumor suppressor gene in clear cell renal cell carcinoma. Cancer Res 70(11):4287–4291

    Article  CAS  PubMed  Google Scholar 

  13. Guo G, Gui Y, Gao S, et al. (2012) Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma. Nat Genet 44(1):17–19

    Article  CAS  Google Scholar 

  14. Peña-Llopis S, Vega-Rubín-de-Celis S, Liao A, et al. (2012) BAP1 loss defines a new class of renal cell carcinoma. Nat Genet 44(7):751–759

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Varela I, Tarpey P, Raine K, et al. (2011) Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 469(7331):539–542

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Gerlinger M, Rowan AJ, Horswell S, et al. (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366(10):883–892

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Kreso A, O’Brien CA, van Galen P, et al. (2013) Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. Science 339:543–548

    Article  CAS  PubMed  Google Scholar 

  18. Beroukhim R, Mermel CH, Porter D, et al. (2010) The landscape of somatic copy-number alteration across human cancers. Nature 463:899–905

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Sato Y, Yoshizato T, Shiraishi Y, et al. (2013) Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet 45(8):860–867

    Article  CAS  PubMed  Google Scholar 

  20. Forbes SA, Beare D, Boutselakis H, et al. (2017) COSMIC: somatic cancer genetics at high-resolution. Nucleic Acids Res 45(D1):D777–D783. http://cancer.sanger.ac.uk. Accessed 31 Jan 2018

  21. Brugarolas J (2014) Molecular genetics of clear-cell renal cell carcinoma. J Clin Oncol 32(18):1968–1976

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Stebbins CE, Kaelin WG Jr, Pavletich NP (1999) Structure of the VHL-ElonginC–ElonginB complex: implications for VHL tumor suppressor function. Science 284:455–461

    Article  CAS  PubMed  Google Scholar 

  23. Maxwell PH, Wiesener MS, Chang GW, et al. (1999) The tumor suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399(6733):271–275

    Article  CAS  PubMed  Google Scholar 

  24. Kim BJ, Kim JH, Kim HS, Zang DY (2017) Prognostic and predictive value of VHL gene alteration in renal cell carcinoma: a meta-analysis and review. Oncotarget 8(8):13979–13985

    PubMed  PubMed Central  Google Scholar 

  25. Nargund AM, Osmanbeyoglu HU, Cheng EH, et al. (2017) SWI/SNF tumor suppressor gene PBRM1/BAF180 in human clear cell kidney cancer. Mol Cell Oncol 4(4):e1342747

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Joseph RW, Kapur P, Serie DJ, et al. (2016) Clear cell renal cell carcinoma subtypes identified by BAP1 and PBRM1 expression. J Urol 195(1):180–187

    Article  CAS  PubMed  Google Scholar 

  27. Kim SH, Park WS, Park EY, et al. (2017) The prognostic value of BAP1, PBRM1, pS6, PTEN, TGase2, PD-L1, CA9, PSMA, and Ki-67 tissue markers in localized renal cell carcinoma: a retrospective study of tissue microarrays using immunohistochemistry. PLoS ONE 12(6):e0179610

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Fay AP, de Velasco G, Ho TH, et al. (2016) Whole-exome sequencing in two extreme phenotypes of response to VEGF-targeted therapies in patients with metastatic clear cell renal cell carcinoma. J Natl Compr Canc Netw 14(7):820–824

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Hsieh JJ, Chen D, Wang PI, et al. (2017) Genomic biomarkers of a randomized trial comparing first-line everolimus and sunitinib in patients with metastatic renal cell carcinoma. Eur Urol 71(3):405–414

    Article  CAS  PubMed  Google Scholar 

  30. Miao D, Margolis CA, Gao W, et al. (2018) Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science . https://doi.org/10.1126/science.aan5951

    Article  PubMed  PubMed Central  Google Scholar 

  31. Liao L, Testa JR, Yang H (2015) The roles of chromatin-remodelers and epigenetic modifiers in kidney cancer. Cancer Genet 208(5):206–214

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Bielecka ZF, Czarnecka AM, Szczylik C (2014) Genomic analysis as the first step toward personalized treatment in renal cell carcinoma. Front Oncol 4:194

    Article  PubMed  PubMed Central  Google Scholar 

  33. Kapur P, Peña-Llopis S, Christie A, et al. (2013) Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal cell carcinoma: a retrospective analysis with independent validation. Lancet Oncol 14(2):159–167

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Hakimi AA, Ostrovnaya I, Reva B, et al. (2013) Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network. Clin Cancer Res 19(12):3259–3267

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Ge Y-Z, Xu L-W, Zhou C-C, et al. (2017) A BAP1 mutation-specific MicroRNA signature predicts clinical outcomes in clear cell renal cell carcinoma patients with wild-type BAP1. J Cancer 8(13):2643–2652

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Manley BJ, Zabor EC, Casuscelli J, et al. (2016) Integration of recurrent somatic mutations with clinical outcomes: a pooled analysis of 1049 patients with clear cell renal cell carcinoma. Eur Urol Focus . https://doi.org/10.1016/j.euf.2016.06.015

    Article  PubMed  PubMed Central  Google Scholar 

  37. Tennenbaum DM, Manley BJ, Zabor E, et al. (2017) Genomic alterations as predictors of survival among patients within a combined cohort with clear cell renal cell carcinoma undergoing cytoreductive nephrectomy. Urol Oncol 35(8):532.e7–537.e13

    Article  CAS  Google Scholar 

  38. Liu W, Fu Q, An H, et al. (2015) Decreased expression of SETD2 predicts unfavorable prognosis in patients with nonmetastatic clear-cell renal cell carcinoma. Medicine 94(45):e2004

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Hoffmann I, Roatsch M, Schmitt ML, et al. (2012) The role of histone demethylases in cancer therapy. Mol Oncol 6(6):683–703

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Manley BJ, Reznik E, Ghanaat M, et al. (2017) Characterizing recurrent and lethal small renal masses in clear cell renal cell carcinoma using recurrent somatic mutations. Urol Oncol . https://doi.org/10.1016/j.urolonc.2017.10.012

    Article  PubMed  PubMed Central  Google Scholar 

  41. Ho TH, Choueiri TK, Wang K, et al. (2016) Correlation between molecular subclassifications of clear cell renal cell carcinoma and targeted therapy response. Eur Urol Focus 2(2):204–209

    Article  PubMed  Google Scholar 

  42. Chaturvedi P, Singh AP, Chakraborty S, et al. (2008) MUC4 mucin interacts with and stabilizes the HER2 oncoprotein in human pancreatic cancer cells. Cancer Res 68(7):2065–2070

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Ponnusamy MP, Singh AP, Jain M, et al. (2008) MUC4 activates HER2 signalling and enhances the motility of human ovarian cancer cells. Br J Cancer 99(3):520–526

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Fu H, Liu Y, Xu L, et al. (2016) Low expression of mucin-4 predicts poor prognosis in patients with clear-cell renal cell carcinoma. Medicine 95(17):e3225

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Finlay CA, Hinds PW, Levine AJ (1989) The p53 proto-oncogene can act as a suppressor of transformation. Cell 57(7):1083–1093

    Article  CAS  PubMed  Google Scholar 

  46. Baker SJ, Fearon ER, Nigro JM, et al. (1989) Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 244(4901):217–221

    Article  CAS  PubMed  Google Scholar 

  47. Santibáñez-Koref MF, Birch JM, Hartley AL, et al. (1991) p53 germline mutations in Li–Fraumeni syndrome. Lancet 338(8781):1490–1491

    Article  PubMed  Google Scholar 

  48. Jamshidi N, Jonasch E, Zapala M, et al. (2015) The radiogenomic risk score: construction of a prognostic quantitative, noninvasive image-based molecular assay for renal cell carcinoma. Radiology 277(1):114–123

    Article  PubMed  Google Scholar 

  49. Jamshidi N, Jonasch E, Zapala M, et al. (2016) The radiogenomic risk score stratifies outcomes in a renal cell cancer phase 2 clinical trial. Eur Radiol 26(8):2798–2807

    Article  PubMed  Google Scholar 

  50. Mazurowski MA (2015) Radiogenomics: what it is and why it is important. J Am Coll Radiol 12(8):862–866

    Article  PubMed  Google Scholar 

  51. Bai HX, Lee AM, Yang L, et al. (2016) Imaging genomics in cancer research: limitations and promises. Br J Radiol 89(1061):20151030

    Article  PubMed  PubMed Central  Google Scholar 

  52. Lawrence MS, Stojanov P, Polak P, et al. (2013) Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499:214–218

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. O’Connor JPB, Rose CJ, Waterton JC, et al. (2014) Imaging intratumor heterogeneity: role in therapy response, resistance, and clinical outcome. Clin Cancer Res 21:249–257

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Kwiatkowski DJ, Choueiri TK, Fay AP, et al. (2016) Mutations in TSC1, TSC2, and MTOR are associated with response to rapalogs in patients with metastatic renal cell carcinoma. Clin Cancer Res 22(10):2445–2452

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Gevaert O, Mitchell LA, Achrol AS, et al. (2014) Glioblastoma multiforme: exploratory radiogenomic analysis by using quantitative image features. Radiology 273(1):168–174

    Article  PubMed  Google Scholar 

  56. Esquela-Kerscher A, Slack FJ (2006) Oncomirs—microRNAs with a role in cancer. Nat Rev Cancer 6(4):259–269

    Article  CAS  PubMed  Google Scholar 

  57. Gámez-Pozo A, Antón-Aparicio LM, Bayona C, et al. (2012) MicroRNA expression profiling of peripheral blood samples predicts resistance to first-line sunitinib in advanced renal cell carcinoma patients. Neoplasia 14:1144–1152

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Khella HWZ, Daniel N, Youssef L, et al. (2017) miR-10b is a prognostic marker in clear cell renal cell carcinoma. J Clin Pathol 70(10):854–859

    Article  CAS  PubMed  Google Scholar 

  59. Weiss GJ, Ganeshan B, Miles KA, et al. (2014) Noninvasive image texture analysis differentiates K-ras mutation from pan-wildtype NSCLC and is prognostic. PLoS ONE 9(7):e100244

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Miles KA, Ganeshan B, Hayball MP (2013) CT texture analysis using the filtration-histogram method: what do the measurements mean? Cancer Imaging 13(3):400–406

    Article  PubMed  PubMed Central  Google Scholar 

  61. Chee CG, Kim YH, Lee KH, et al. (2017) CT texture analysis in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy: a potential imaging biomarker for treatment response and prognosis. PLoS ONE 12(8):e0182883

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Goh V, Ganeshan B, Nathan P, et al. (2011) Assessment of response to tyrosine kinase inhibitors in metastatic renal cell cancer: CT texture as a predictive biomarker. Radiology 261(1):165–171

    Article  PubMed  Google Scholar 

  63. Lubner MG, Stabo N, Abel EJ, Del Rio AM, Pickhardt PJ (2016) CT textural analysis of large primary renal cell carcinomas: pretreatment tumor heterogeneity correlates with histologic findings and clinical outcomes. AJR 207(1):96–105

    Article  PubMed  Google Scholar 

  64. Haider MA, Vosough A, Khalvati F, et al. (2017) CT texture analysis: a potential tool for prediction of survival in patients with metastatic clear cell carcinoma treated with sunitinib. Cancer Imaging 17:4

    Article  PubMed  PubMed Central  Google Scholar 

  65. Rios Velazquez E, Parmar C, Liu Y, et al. (2017) Somatic mutations drive distinct imaging phenotypes in lung cancer. Cancer Res 77(14):3922–3930

    Article  CAS  PubMed  Google Scholar 

  66. Yin Q, Hung S-C, Wang L, et al. (2017) Associations between tumor vascularity, vascular endothelial growth factor expression and PET/MRI radiomic signatures in primary clear-cell–renal-cell-carcinoma: proof-of-concept study. Sci Rep 7:43356

    Article  PubMed  PubMed Central  Google Scholar 

  67. Aerts HJWL (2017) Data science in radiology: a path forward. Clin Cancer Res . https://doi.org/10.1158/1078-0432.CCR-17-2804

    Article  PubMed  PubMed Central  Google Scholar 

  68. Aerts HJWL, Grossmann P, Tan Y, et al. (2016) Defining a radiomic response phenotype: a pilot study using targeted therapy in NSCLC. Sci Rep 6:33860

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Li Z, Wang Y, Yu J, Guo Y, Cao W (2017) Deep learning based radiomics (DLR) and its usage in noninvasive IDH1 prediction for low grade glioma. Sci Rep 7:5467

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Aerts HJ (2016) The potential of radiomic-based phenotyping in precision medicine: a review. JAMA Oncol 2(12):1636–1642

    Article  PubMed  Google Scholar 

  71. Aerts HJ, Velazquez ER, Leijenaar R, et al. (2014) Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun 3(5):4006

    Article  CAS  Google Scholar 

  72. Weinstein JN, Collisson EA, Mills GB, et al. (2013) The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet 45(10):1113–1120

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Clark K, Vendt B, Smith K, et al. (2013) The Cancer Imaging Archive (TCIA): maintaining and operating a public information repository. J Digit Imaging 26(6):1045–1057

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Imaging, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA, 02215, USA

    Francesco Alessandrino, Atul B. Shinagare & Katherine M. Krajewski

  2. Department of Radiology, Brigham and Women’s Hospital, Harvard Medical School, 75 Francis Street, Boston, MA, 02115, USA

    Francesco Alessandrino, Atul B. Shinagare & Katherine M. Krajewski

  3. Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Dana 1230, Boston, MA, 02215, USA

    Dominick Bossé & Toni K. Choueiri

Authors
  1. Francesco Alessandrino
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Atul B. Shinagare
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dominick Bossé
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Toni K. Choueiri
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Katherine M. Krajewski
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Francesco Alessandrino.

Ethics declarations

Funding

No funding was received for this study.

Conflict of interest

Francesco Alessandrino, MD: no conflict of interest to declare. Atul B. Shinagare, MD: Consultant, Arog Pharmaceuticals; research funding, GTx Inc. Dominick Bossé, MD: no conflict of interest to declare. Toni K. Choueiri, MD: Research funding by AstraZeneca, BMS, Exelixis, Genentech, GSK, Merck, Novartis, Peloton, Pfizer, Roche, Tracon, Eisai. Katherine M. Krajewski, MD: no conflict of interest to declare.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

Statement of informed consent is not applicable since the manuscript does not contain any patient data.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Alessandrino, F., Shinagare, A.B., Bossé, D. et al. Radiogenomics in renal cell carcinoma. Abdom Radiol 44, 1990–1998 (2019). https://doi.org/10.1007/s00261-018-1624-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00261-018-1624-y

Keywords

Search

Navigation